- Home
- SPFI vs VIR Comparison
SPFI vs VIR Comparison
Compare SPFI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- VIR
- Stock Information
- Founded
- SPFI 1941
- VIR 2016
- Country
- SPFI United States
- VIR United States
- Employees
- SPFI N/A
- VIR N/A
- Industry
- SPFI Major Banks
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- VIR Health Care
- Exchange
- SPFI Nasdaq
- VIR Nasdaq
- Market Cap
- SPFI 662.8M
- VIR 706.4M
- IPO Year
- SPFI 2019
- VIR 2019
- Fundamental
- Price
- SPFI $39.29
- VIR $4.86
- Analyst Decision
- SPFI Buy
- VIR Strong Buy
- Analyst Count
- SPFI 3
- VIR 11
- Target Price
- SPFI $41.67
- VIR $25.73
- AVG Volume (30 Days)
- SPFI 43.0K
- VIR 1.5M
- Earning Date
- SPFI 10-22-2025
- VIR 10-30-2025
- Dividend Yield
- SPFI 1.49%
- VIR N/A
- EPS Growth
- SPFI 19.09
- VIR N/A
- EPS
- SPFI 3.20
- VIR N/A
- Revenue
- SPFI $199,001,000.00
- VIR $19,000,000.00
- Revenue This Year
- SPFI $13.41
- VIR N/A
- Revenue Next Year
- SPFI $6.10
- VIR $11.08
- P/E Ratio
- SPFI $12.61
- VIR N/A
- Revenue Growth
- SPFI 7.49
- VIR N/A
- 52 Week Low
- SPFI $30.01
- VIR $4.16
- 52 Week High
- SPFI $42.38
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- SPFI 45.89
- VIR 47.49
- Support Level
- SPFI $39.40
- VIR $5.04
- Resistance Level
- SPFI $40.93
- VIR $5.39
- Average True Range (ATR)
- SPFI 1.02
- VIR 0.35
- MACD
- SPFI -0.21
- VIR -0.01
- Stochastic Oscillator
- SPFI 5.76
- VIR 10.28
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.